D
David Gloss
Researcher at Geisinger Health System
Publications - 24
Citations - 4950
David Gloss is an academic researcher from Geisinger Health System. The author has contributed to research in topics: Epilepsy & Guideline. The author has an hindex of 18, co-authored 22 publications receiving 3599 citations. Previous affiliations of David Gloss include St. Joseph's Hospital and Medical Center & Geisinger Medical Center.
Papers
More filters
Journal ArticleDOI
Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
Ronald C. Petersen,Oscar L. Lopez,Melissa J. Armstrong,Thomas S.D. Getchius,Mary Ganguli,David Gloss,Gary S. Gronseth,Daniel C. Marson,Tamara Pringsheim,Gregory S. Day,Mark A. Sager,James C. Stevens,Alexander Rae-Grant +12 more
TL;DR: In patients with MCI, exercise training (6 months) is likely to improve cognitive measures and cognitive training may improve cognitive Measures, and no high-quality evidence exists to support pharmacologic treatments for MCI.
Journal ArticleDOI
Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society
Tracy A. Glauser,Shlomo Shinnar,David Gloss,Brian K. Alldredge,Ravindra Arya,Jacquelyn L. Bainbridge,Mary A Bare,Thomas P. Bleck,W. Edwin Dodson,Lisa Garrity,Andy Jagoda,Daniel H. Lowenstein,John M. Pellock,James Riviello,Edward P. Sloan,David M. Treiman +15 more
TL;DR: Despite the paucity of well-designed randomized controlled trials, practical conclusions and an integrated treatment algorithm for the treatment of convulsive status epilepticus across the age spectrum (infants through adults) can be constructed.
Journal ArticleDOI
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders Report of the Guideline Development Subcommittee of the American Academy of Neurology
Barbara S. Koppel,John C.M. Brust,Terry D. Fife,Jeff M. Bronstein,Sarah Youssof,Gary S. Gronseth,David Gloss +6 more
TL;DR: A systematic review of medical marijuana to address treatment of symptoms of multiple sclerosis, epilepsy, and movement disorders found oral cannabinoids are of unknown efficacy in non–chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy.
Journal ArticleDOI
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M. Simpson,Mark Hallett,Eric J. Ashman,Cynthia L. Comella,Mark W. Green,Gary S. Gronseth,Melissa J. Armstrong,David Gloss,Sonja Potrebic,Joseph Jankovic,Barbara P. Karp,Markus Naumann,Yuen T. So,Stuart A. Yablon +13 more
TL;DR: The 2008 AAN guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia, headache, and adult spasticity are updated and onaBoNT-A is established as ineffective and should not be offered for episodic migraine and is probably ineffective for chronic tension-type headaches.
Journal ArticleDOI
Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Cynthia L. Harden,T. Tomson,David Gloss,Jeffrey Buchhalter,J. Helen Cross,Elizabeth J. Donner,Jacqueline A. French,Anthony Gil-Nagel,Dale C. Hesdorffer,W. Henry Smithson,Mark C. Spitz,Thaddeus S. Walczak,Josemir W. Sander,Philippe Ryvlin +13 more
TL;DR: The major risk factor for SUDEP is the occurrence of generalized tonic-clonic seizures (GTCS); the SUDEP risk increases in association with increasing frequency of GTCS occurrence (high confidence in evidence).